Blockade of IL-6 using tocilizumab, an approved treatment for RA and other autoimmune disorders, has been shown to correlate with increased frequency of Treg cells, although Treg function was not assessed in these settings (17–20). Here, IL6 is linked to rheumatoid arthritis.